354 Lenvatinib and pembrolizumab in advanced endometrial carcinoma (EC): long-term efficacy and safety update from a phase 1b/2 study

• Emmett Schmidt,
• Matthew Taylor,
• Allen Cohn,
• Corina Dutcus,
• Marcia Brose,
• Robert Orlowski,
• Jie Huang,
• Carol Aghajanian,
• Margarita Romeo,
• Raquel Bratos,
• Mark Messing,
• Lea Dutta

Affiliations

Emmett Schmidt

Aff145 grid.417993.10000000122600793Merck & Co., Inc. Kenilworth NJ USA

Matthew Taylor

3Providence Cancer Institute, Portland, OR, USA

Allen Cohn

Aff20 McKesson Specialty Health Las Vegas NV USA

Corina Dutcus

Aff21 0000 0004 0599 8842grid.418767.bEisai Inc. Woodcliff Lake NJ USA

Marcia Brose

Aff24 0000 0004 0454 0768grid.412701.1Abramson Cancer Center of the University Philadelphia PA USA

Robert Orlowski

Aff6 grid.240145.60000000122914776The University of Texas MD Anderson Cancer Center Houston TX USA

Jie Huang

Department of In Vitro Diagnostic Reagent, National Institutes for Food and Drug Control, Beijing, China

Carol Aghajanian

Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Margarita Romeo

4Catalan Institute of Oncology, Badalona, Spain

Raquel Bratos

5MD Anderson Cancer Center España, Madrid, Spain

Mark Messing

7Texas Oncology, Bedford, TX, USA

Lea Dutta

8Eisai Inc., Woodcliff Lake, NJ, USA